J Allergy Clin Immunol:鼻息肉与未来头颈癌风险研究

2019-07-17 AlexYang MedSci原创

鼻息肉是一种常见的疾病,并且显著的影响生活质量。鼻息肉与头颈癌风险的相关性仍旧未知。最近,有研究人员在一个基于群体的回顾性鼻息肉患者以及匹配的比较者中调查了鼻腔鼻窦(NCPS)和鼻咽肿瘤的相对风险情况。研究包括了453892名鼻息肉患者和4583938名匹配的比较者。平均跟踪调查时间为6.2年(范围2-13年)。鼻息肉患者与比较这NCPS的发生比值为7.00(95% CI: 5.28-9.25),

鼻息肉是一种常见的疾病,并且显著的影响生活质量。鼻息肉与头颈癌风险的相关性仍旧未知。最近,有研究人员在一个基于群体的回顾性鼻息肉患者以及匹配的比较者中调查了鼻腔鼻窦(NCPS)和鼻咽肿瘤的相对风险情况。

研究包括了453892名鼻息肉患者和4583938名匹配的比较者。平均跟踪调查时间为6.2年(范围2-13年)。鼻息肉患者与比较这NCPS的发生比值为7.00(95% CI: 5.28-9.25),鼻咽肿瘤为1.78(95% CI: 1.28-2.42)。另外,这些癌症风险的增加仅仅只在老年受试者中明显(年龄不小于50岁)。鼻息肉与这些癌症的相关性在年轻的并发哮喘或者过敏性鼻炎受试者中倾向于减弱。

最后,研究人员指出,尽管癌症的绝对发生率很低,NCPS或者鼻炎肿瘤的相对风险在老年鼻息肉患者中显著更高。考虑到鼻息肉的区域和病理异质性,还需进一步的研究来确定潜在的机制的关系。

原始出处:

Kim HJ, Ahn HS, Kang T et al. Nasal Polyps and Future Risk of Head and Neck Cancer: A Nationwide Population-based Cohort Study. J Allergy Clin Immunol. 03 Jul 2019

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2055668, encodeId=25672055668cc, content=<a href='/topic/show?id=734110089320' target=_blank style='color:#2F92EE;'>#风险研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100893, encryptionId=734110089320, topicName=风险研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Feb 23 13:10:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061862, encodeId=2ca72061862de, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Mon Dec 09 05:10:00 CST 2019, time=2019-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295897, encodeId=dc99129589e6f, content=<a href='/topic/show?id=f30a4441598' target=_blank style='color:#2F92EE;'>#头颈癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44415, encryptionId=f30a4441598, topicName=头颈癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Fri Jul 19 06:10:00 CST 2019, time=2019-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329260, encodeId=1ff9132926087, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Fri Jul 19 06:10:00 CST 2019, time=2019-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369872, encodeId=67313698e2ec, content=有趣, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/07/13/c48064d3b7f86e87115574719fd684e6.jpg, createdBy=814a5140228, createdName=jefflin520, createdTime=Thu Jul 18 09:49:53 CST 2019, time=2019-07-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2055668, encodeId=25672055668cc, content=<a href='/topic/show?id=734110089320' target=_blank style='color:#2F92EE;'>#风险研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100893, encryptionId=734110089320, topicName=风险研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Feb 23 13:10:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061862, encodeId=2ca72061862de, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Mon Dec 09 05:10:00 CST 2019, time=2019-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295897, encodeId=dc99129589e6f, content=<a href='/topic/show?id=f30a4441598' target=_blank style='color:#2F92EE;'>#头颈癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44415, encryptionId=f30a4441598, topicName=头颈癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Fri Jul 19 06:10:00 CST 2019, time=2019-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329260, encodeId=1ff9132926087, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Fri Jul 19 06:10:00 CST 2019, time=2019-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369872, encodeId=67313698e2ec, content=有趣, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/07/13/c48064d3b7f86e87115574719fd684e6.jpg, createdBy=814a5140228, createdName=jefflin520, createdTime=Thu Jul 18 09:49:53 CST 2019, time=2019-07-18, status=1, ipAttribution=)]
    2019-12-09 sjq027
  3. [GetPortalCommentsPageByObjectIdResponse(id=2055668, encodeId=25672055668cc, content=<a href='/topic/show?id=734110089320' target=_blank style='color:#2F92EE;'>#风险研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100893, encryptionId=734110089320, topicName=风险研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Feb 23 13:10:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061862, encodeId=2ca72061862de, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Mon Dec 09 05:10:00 CST 2019, time=2019-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295897, encodeId=dc99129589e6f, content=<a href='/topic/show?id=f30a4441598' target=_blank style='color:#2F92EE;'>#头颈癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44415, encryptionId=f30a4441598, topicName=头颈癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Fri Jul 19 06:10:00 CST 2019, time=2019-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329260, encodeId=1ff9132926087, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Fri Jul 19 06:10:00 CST 2019, time=2019-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369872, encodeId=67313698e2ec, content=有趣, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/07/13/c48064d3b7f86e87115574719fd684e6.jpg, createdBy=814a5140228, createdName=jefflin520, createdTime=Thu Jul 18 09:49:53 CST 2019, time=2019-07-18, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2055668, encodeId=25672055668cc, content=<a href='/topic/show?id=734110089320' target=_blank style='color:#2F92EE;'>#风险研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100893, encryptionId=734110089320, topicName=风险研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Feb 23 13:10:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061862, encodeId=2ca72061862de, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Mon Dec 09 05:10:00 CST 2019, time=2019-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295897, encodeId=dc99129589e6f, content=<a href='/topic/show?id=f30a4441598' target=_blank style='color:#2F92EE;'>#头颈癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44415, encryptionId=f30a4441598, topicName=头颈癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Fri Jul 19 06:10:00 CST 2019, time=2019-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329260, encodeId=1ff9132926087, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Fri Jul 19 06:10:00 CST 2019, time=2019-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369872, encodeId=67313698e2ec, content=有趣, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/07/13/c48064d3b7f86e87115574719fd684e6.jpg, createdBy=814a5140228, createdName=jefflin520, createdTime=Thu Jul 18 09:49:53 CST 2019, time=2019-07-18, status=1, ipAttribution=)]
    2019-07-19 膀胱癌
  5. [GetPortalCommentsPageByObjectIdResponse(id=2055668, encodeId=25672055668cc, content=<a href='/topic/show?id=734110089320' target=_blank style='color:#2F92EE;'>#风险研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100893, encryptionId=734110089320, topicName=风险研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Sun Feb 23 13:10:00 CST 2020, time=2020-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061862, encodeId=2ca72061862de, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d58a435, createdName=sjq027, createdTime=Mon Dec 09 05:10:00 CST 2019, time=2019-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295897, encodeId=dc99129589e6f, content=<a href='/topic/show?id=f30a4441598' target=_blank style='color:#2F92EE;'>#头颈癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44415, encryptionId=f30a4441598, topicName=头颈癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c32257, createdName=DEXTER3139, createdTime=Fri Jul 19 06:10:00 CST 2019, time=2019-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329260, encodeId=1ff9132926087, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Fri Jul 19 06:10:00 CST 2019, time=2019-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369872, encodeId=67313698e2ec, content=有趣, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/07/13/c48064d3b7f86e87115574719fd684e6.jpg, createdBy=814a5140228, createdName=jefflin520, createdTime=Thu Jul 18 09:49:53 CST 2019, time=2019-07-18, status=1, ipAttribution=)]
    2019-07-18 jefflin520

    有趣

    0

相关资讯

赛诺菲:Dupixent(dupilumab)治疗严重慢性鼻窦炎、鼻息肉的两项III期临床试验取得了积极成果


两项III期试验(SINUS-24和SINUS-52)对患有复发性慢性鼻窦炎和鼻息肉(CRSwNP)的患者进行了详细的研究,这些患者先前接受了手术和/或全身性皮质类固醇治疗。Dupixent(dupilumab)在加入到标准皮质类固醇鼻腔喷雾剂时可改善鼻息肉大小、鼻充血严重程度、慢性鼻窦疾病、嗅觉和咳嗽。

Int Forum Allergy Rhinol:11年之间中国鼻息肉慢性鼻窦炎患者的临床和组织特性变化

传统上认为,中国鼻息肉慢性鼻窦炎(CRSwNP)患者要比北美和欧洲患者具有更少的嗜酸性细胞和更多的中性粒细胞炎症。然而,炎症模式可能随着时间而变化。最近,有研究人员分析了中国患者CRSwNP临床和组织特性随着时间变化的趋势情况。研究包括了2003年到2005年间的115名连续性CRSwNP患者和2014年到2016年114名连续性CRSwNP患者。研究发现,在11年研究期间,嗜酸性粒细胞在鼻息肉组

J Allergy Clin Immunol:鼻息肉慢性鼻窦炎患者中免疫球蛋白G能够调控促炎性lgE响应

鼻息肉慢性鼻窦炎(CRSwNP)通常可以通过多克隆lgE个体基因型的局部产生来鉴定。虽然组织lgE浓度能够达到几千kU/L,鼻息肉中lgE调节的炎症是通过怎样的机制来调控的仍旧不清楚。最近,有研究人员探索了是否鼻息肉中局部诱导的lgG抗体能够抑制lgE调节的促炎性响应。研究人员从草花粉过敏的CRSwNP和非过敏性对照受试者中采集了鼻息肉匀浆。研究发现,鼻息肉中,lgG在控制lgE调节的炎症响应方面

Nature:RNA单细胞测序技术意外找到了慢性鼻炎的根源

MIT、Brigham和妇女医院的研究人员对来自人类患者的数千个单细胞进行了全基因组分析,创建了炎症期间人类屏障组织的第一张整体细胞图谱,通过对这些数据分析,他们找到了一个可以解释慢性鼻窦炎病因的新机制。

FDA批准将赛诺菲/再生元的IL-4/IL-13单抗Dupixent用于治疗鼻息肉

赛诺菲和Regeneron宣布其IL-4/IL-13单抗Dupixent获得美国食品和药物管理局批准,用于治疗患有慢性鼻窦炎和鼻息肉的成人患者。

Rhinology: 额外神经元TRPV1在患有鼻息肉的慢性鼻窦炎患者中表达上调

慢性鼻窦炎(CRS)是一种多音字的上呼吸道疾病,并且病因学仍旧不清楚。瞬态电压感受器阳离子通道1(TRPV1)和瞬态电压感受电位锚定蛋白1(TRPA1)通道在CRS的病理学中具有复杂的关系。最近,有研究人员进行了旨在检测额外神经元TRPV1和TRPA1受体在鼻息肉(NP)组织样本中的表达情况。研究发现,非神经元TRPV1和TRPA1受体在NP生物样本中表达。肥大细胞和巨噬细胞对TRPV1和TRPA